ReviewMolecular biotechnology2026
The Role of Neutrophil Extracellular Traps (NETs) in the Pathogenesis of Ovarian Cancer: New Insight and Future Perspectives.
Review in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Context-dependent roles of HtrA2/Omi in ovarian cancer: mitochondrial apoptotic function linking platinum sensitivity and acquired chemoresistance-a narrative review.Translational cancer research · 2026Review
- The Tumor-Platelet-Immune Interface: Driving Metastasis, Pre-Metastatic Niche Formation and Therapeutic Vulnerabilities.Expert reviews in molecular medicine · 2026Review
- Neutrophils and NETosis in polycystic ovary syndrome: unraveling the immuno-metabolic thromboinflammatory axis.European journal of medical research · 2026Review
- Neutrophil extracellular traps in gynecological disease: pathogenic mechanisms and therapeutic opportunities.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is a highly heterogeneous malignancy characterized by genetic diversity, clonal evolution, and therapeutic resistance, making it one of the deadliest gynecologic cancers worldwide. Neutrophil extracellular traps (NETs), composed of DNA, histones, and proteases, have emerged as critical mediators of tumor progression. This review comprehensively examines the interplay between neutrophils and ovarian cancer cells, emphasizing the role of NETs in shaping the tumor microenvironment and promoting disease progression. We critically analyze recent literature on the mechanisms by which NETs influence ovarian cancer metastasis, immune evasion, and chemoresistance. Furthermore, we discuss potential therapeutic strategies aimed at targeting NET formation to improve patient outcomes. NETs actively contribute to ovarian cancer progression by fostering a protumorigenic microenvironment, enhancing metastatic potential, and impeding the efficacy of standard therapies. Disrupting NET-associated pathways, including platelet-neutrophil interactions, represents a promising avenue for intervention. Emerging strategies, such as antiplatelet agents, have shown potential in modulating NET activity. However, their clinical application remains in early investigational stages, necessitating further research. This review underscores the pivotal role of NETs in ovarian cancer biology and highlights their potential as therapeutic targets. Although novel approaches, including antiplatelet agents, offer promising avenues for disrupting NET-driven tumor progression, their translational feasibility requires further validation. A deeper understanding of NET-mediated mechanisms could pave the way for innovative therapeutic strategies to enhance ovarian cancer treatment and improve patient survival.
Indexed as
Identifiers
40650703What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.